Astroglial PGC-1alpha increases mitochondrial antioxidant capacity and suppresses inflammation: Implications for multiple sclerosis

Acta Neuropathologica Communications

Volumn 2, Issue 1, 2014, Pages

  Nijland, Philip G ^a   Witte, Maarten E ^a,c   van het Hof, Bert ^a   van der Pol, Susanne ^a   Bauer, Jan ^b   Lassmann, Hans ^b   van der Valk, Paul ^a   de Vries, Helga E ^a   van Horssen, Jack ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Medical University of Vienna   (Austria)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

Neurodegeneration; Prx3; Reactive astrocytes; ROS; Trx2

Indexed keywords

ANTIOXIDANT; CYTOKINE; PEROXIREDOXIN 3; PPARGC1A PROTEIN, HUMAN; PRDX3 PROTEIN, HUMAN; PROTEOLIPID PROTEIN; REACTIVE OXYGEN METABOLITE; THIOREDOXIN; TRANSCRIPTION FACTOR;

ADULT; AGED; ASTROCYTE; BRAIN; CASE CONTROL STUDY; CELL CULTURE; COMPLICATION; ENCEPHALITIS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; MULTIPLE SCLEROSIS; OXIDATIVE STRESS; PATHOLOGY; PHYSIOLOGY; WHITE MATTER;

ADULT; AGED; ANTIOXIDANTS; ASTROCYTES; BRAIN; CASE-CONTROL STUDIES; CELLS, CULTURED; CYTOKINES; ENCEPHALITIS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MYELIN PROTEOLIPID PROTEIN; OXIDATIVE STRESS; PEROXIREDOXIN III; REACTIVE OXYGEN SPECIES; THIOREDOXINS; TRANSCRIPTION FACTORS; WHITE MATTER;

EID: 84965086726     PISSN: None     EISSN: 20515960     Source Type: Journal    
DOI: 10.1186/s40478-014-0170-2     Document Type: Article

References (60)

1. Compston A: McAlpine's Multiple Sclerosis. 2005.
2. Frohman EM, Racke MK, Raine CS: Multiple Sclerosis-the Plaque and Its Pathogenesis. N Engl J Med 2006, 354: 942-955. 10.1056/NEJMra052130
3. Fischer MT, Sharma R, Lim JL, Haider L, Frischer JM, Drexhage J, Mahad D, Bradl M, van Horssen J, Lassmann H: NADPH Oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. Brain 2012, 135: 886-899. 10.1093/brain/aws012
4. Brosnan CF, Raine CS: The astrocyte in multiple sclerosis revisited. Glia 2013, 61: 453-465. 10.1002/glia.22443
5. Miljkovi-ç D, Timotijevi-ç G, Stojkovi-ç MM: Astrocytes in the tempest of multiple sclerosis. FEBS Lett 2011, 585: 3781-3788. 10.1016/j.febslet.2011.03.047
6. Doorn R, Nijland P, Dekker N, Witte M, Lopes-Pinheiro M, van het Hof B, Kooij G, Reijerkerk A, Dijkstra C, Valk P, Horssen J, Vries H: Fingolimod attenuates ceramide-induced BloodGÇôbrain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes. Acta Neuropathol 2012, 124: 397-410. 10.1007/s00401-012-1014-4
7. Mizee M, Nijland P, van der Pol S, Drexhage J, van het Hof B, Mebius R, van der Valk P, van Horssen J, Reijerkerk A, de Vries H: Astrocyte-derived retinoic acid: a novel regulator of BloodGÇôbrain barrier function in multiple sclerosis. Acta Neuropathol 2014, 128(5):691-703. 10.1007/s00401-014-1335-6
8. Sofroniew M, Vinters H: Astrocytes: biology and pathology. Acta Neuropathol 2010, 119: 7-35. 10.1007/s00401-009-0619-8
9. Kostianovsky AM, Maier LM, Anderson RC, Bruce JN, Anderson DE: Astrocytic regulation of human monocytic/microglial activation. J Immunol 2008, 181: 5425-5432. 10.4049/jimmunol.181.8.5425
10. Van Horssen J, Schreibelt G, Drexhage J, Hazes T, Dijkstra CD, van der Valk P, De Vries HE: Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression. Free Radic Biol Med 2008, 45: 1729-1737. 10.1016/j.freeradbiomed.2008.09.023
11. Liddell JR, Robinson SR, Dringen R, Bishop GM: Astrocytes retain their antioxidant capacity into advanced old age. Glia 2010, 58: 1500-1509.
12. Witte ME, Mahad DJ, Lassmann H, van Horssen J: Mitochondrial dysfunction contributes to neurodegeneration in multiple sclerosis. Trends Mol Med 2014, 20: 179-187. 10.1016/j.molmed.2013.11.007
13. Dutta R, McDonough J, Yin X, Peterson J, Chang A, Torres T, Gudz T, Macklin WB, Lewis DA, Fox RJ, Rudick R, Mirnics K, Trapp BD: Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol 2006, 59: 478-489. 10.1002/ana.20736
14. Mahad DJ, Ziabreva I, Campbell G, Lax N, White K, Hanson PS, Lassmann H, Turnbull DM: Mitochondrial changes within axons in multiple sclerosis. Brain 2009, 132: 1161-1174. 10.1093/brain/awp046
15. Witte ME, Bo L, Rodenburg RJ, Belien JA, Musters R, Hazes T, Wintjes LT, Smeitink JA, Geurts JJ, De Vries HE, Van D, Valk P, van Horssen J: Enhanced number and activity of mitochondria in multiple sclerosis lesions. J Pathol 2009, 219: 193-204. 10.1002/path.2582
16. Watabe S, Hiroi T, Yamamoto Y, Fujioka Y, Hasegawa H, Yago N, Takahashi SY: SP-22 Is a thioredoxin-dependent peroxide reductase in mitochondria. Eur J Biochem 1997, 249: 52-60. 10.1111/j.1432-1033.1997.t01-1-00052.x
17. Spyrou G, Enmark E, Miranda-Vizuete A, Gustafsson J: Cloning and expression of a novel mammalian thioredoxin. J Biol Chem 1997, 272: 2936-2941. 10.1074/jbc.272.5.2936
18. Bell KF, Hardingham GE: CNS peroxiredoxins and their regulation in health and disease. Antioxid Redox Signal 2011, 14(8):1467-1477. 10.1089/ars.2010.3567
19. Patenaude A, Murthy MR, Mirault ME: Emerging Roles of thioredoxin cycle enzymes in the central nervous system. Cell Mol Life Sci 2005, 62: 1063-1080. 10.1007/s00018-005-4541-5
20. Hattori F, Murayama N, Noshita T, Oikawa S: Mitochondrial Peroxiredoxin-3 protects hippocampal neurons from excitotoxic injury in vivo. J Neurochem 2003, 86: 860-868. 10.1046/j.1471-4159.2003.01918.x
21. Hwang IK, Yoo KY, Kim DW, Lee CH, Choi JH, Kwon YG, Kim YM, Choi SY, Won MH: Changes in the expression of mitochondrial peroxiredoxin and thioredoxin in neurons and glia and their protective effects in experimental cerebral ischemic damage. Free Radic Biol Med 2010, 48: 1242-1251. 10.1016/j.freeradbiomed.2010.02.007
22. Witte M, Nijland P, Drexhage J, Gerritsen W, Geerts D, het Hof B, Reijerkerk A, Vries H, Valk P, Horssen J: Reduced expression of PGC-1alpha partly underlies mitochondrial changes and correlates with neuronal loss in multiple sclerosis cortex. Acta Neuropathol 2013, 125: 231-243. 10.1007/s00401-012-1052-y
23. Hock MB, Kralli A: Transcriptional control of mitochondrial biogenesis and function. Annu Rev Physiol 2009, 71: 177-203. 10.1146/annurev.physiol.010908.163119
24. Ventura-Clapier R, Garnier A, Veksler V: Transcriptional control of mitochondrial biogenesis: the Central Role of PGC-1alpha. Cardiovasc Res 2008, 79: 208-217. 10.1093/cvr/cvn098
25. Haider L, Fischer MT, Frischer JM, Bauer J, Hoftberger R, Botond G, Esterbauer H, Binder CJ, Witztum JL, Lassmann H: Oxidative damage in multiple sclerosis lesions. Brain 2011, 134: 1914-1924. 10.1093/brain/awr128
26. Nijland PG, Michailidou I, Witte ME, Mizee MR, van der Pol SMA, van het Hof B, Reijerkerk A, Pellerin L, van der Valk P, de Vries HE, van Horssen J: Cellular distribution of glucose and monocarboxylate transporters in human brain white matter and multiple sclerosis lesions. Glia 2014, 62: 1125-1141. 10.1002/glia.22667
27. Bien CG, Vincent A, Barnett MH, Becker AJ, Blümcke I, Graus F, Jellinger KA, Reuss DE, Ribalta T, Schlegel J, Sutton I, Lassmann H, Bauer J: Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain 2012, 135: 1622-1638. 10.1093/brain/aws082
28. Zhang H, Go YM, Jones DP: Mitochondrial Thioredoxin-2/Peroxiredoxin-3 System Functions in Parallel With Mitochondrial GSH System in Protection Against Oxidative Stress. Arch Biochem Biophys 2007, 465: 119-126. 10.1016/j.abb.2007.05.001
29. Nikolic N, Rhedin M, Rustan AC, Storlien L, Thoresen GH, Stromstedt M: Overexpression of PGC-1alpha increases fatty acid oxidative capacity of human skeletal muscle cells. Biochem Res Int 2012, 2012: 714074. 10.1155/2012/714074
30. Garcia-Vallejo JJ, Van DW, van Het HB, Van DI, Engelse MA, Van H,V, Gringhuis SI: Activation of human endothelial cells by tumor necrosis factor-alpha results in profound changes in the expression of glycosylation-related genes. J Cell Physiol 2006, 206: 203-210. 10.1002/jcp.20458
31. Durrenberger P, Fernando F, Magliozzi R, Kashefi S, Bonnert T, Ferrer I, Seilhean D, Nait-Oumesmar B, Schmitt A, Gebicke-Haerter P, Falkai P, Grunblatt E, Palkovits M, Parchi P, Capellari S, Arzberger T, Kretzschmar H, Roncaroli F, Dexter D, Reynolds R: Selection of novel reference genes for Use in the human central nervous system: a BrainNet Europe study. Acta Neuropathol 2012, 124: 893-903. 10.1007/s00401-012-1027-z
32. Kooi EJ, Prins M, Bajic N, Belien JA, Gerritsen WH, Van Horssen J, Aronica E, van D, Hoozemans JJ, Francis PT, Van DV, Geurts JJ: Cholinergic imbalance in the multiple sclerosis hippocampus. Acta Neuropathol 2011, 122: 313-322. 10.1007/s00401-011-0849-4
33. Lassmann H: Review: the architecture of inflammatory demyelinating lesions: implications for studies on pathogenesis. Neuropathol Appl Neurobiol 2011, 37: 698-710. 10.1111/j.1365-2990.2011.01189.x
34. Aquilano K, Vigilanza P, Baldelli S, Pagliei B, Rotilio G, Ciriolo MR: Peroxisome Proliferator-Activated Receptor y Co-Activator 1alpha (PGC-1alpha) and Sirtuin 1 (SIRT1) Reside in Mitochondria. J Biol Chem 2010, 285: 21590-21599. 10.1074/jbc.M109.070169
35. Van Der Voorn P, Tekstra J, Beelen RHJ, Tensen CP, van der Valk P, De Groot CJA: Expression of MCP-1 by reactive astrocytes in demyelinating multiple sclerosis lesions. Am J Pathol 1999, 154: 45-51. 10.1016/S0002-9440(10)65249-2
36. Schonrock LM, Gawlowski G, Bruck W: Interleukin-6 expression in human multiple sclerosis lesions. Neurosci Lett 2000, 294: 45-48. 10.1016/S0304-3940(00)01543-3
37. Tanuma N, Sakuma H, Sasaki A, Matsumoto Y: Chemokine expression by astrocytes plays a role in microglia/macrophage activation and subsequent neurodegeneration in secondary progressive multiple sclerosis. Acta Neuropathol 2006, 112: 195-204. 10.1007/s00401-006-0083-7
38. Handschin C, Choi CS, Chin S, Kim S, Kawamori D, Kurpad AJ, Neubauer N, Hu J, Mootha VK, Kim YB, Kulkarni RN, Shulman GI, Spiegelman BM: Abnormal Glucose Homeostasis in Skeletal MuscleGÇôspecific PGC-1 + | Knockout Mice Reveals Skeletal MuscleGÇôpancreatic + | Cell Crosstalk. J Clin Invest 2007, 117: 3463-3474. 10.1172/JCI31785
39. Mormeneo E, Jimenez-Mallebrera C, Palomer X, De Nigris V, Vazquez-Carrera M, Orozco A, Nascimento A, Colomer J, Lerin C, Gomez-Foix AM: PGC-1alpha induces mitochondrial and myokine transcriptional programs and lipid droplet and glycogen accumulation in cultured human skeletal muscle cells. PLoS One 2012, 7: e29985. 10.1371/journal.pone.0029985
40. Bitsch A, Kuhlmann T, Da CC, Bunkowski S, Polak T, Bruck W: Tumour necrosis factor alpha MRNA expression in early multiple sclerosis lesions: correlation with demyelinating activity and oligodendrocyte pathology. Glia 2000, 29: 366-375. 10.1002/(SICI)1098-1136(20000215)29:4<366::AID-GLIA7>3.0.CO;2-Y
41. Becher B, Giacomini PS, Pelletier D, McCrea E, Prat A, Antel JP: Interferon-gamma secretion by peripheral blood T-cell subsets in multiple sclerosis: correlation with disease phase and interferon-beta therapy. Ann Neurol 1999, 45: 247-250. 10.1002/1531-8249(199902)45:2<247::AID-ANA16>3.0.CO;2-U
42. Bruck W, Porada P, Poser S, Rieckmann P, Hanefeld F, Kretzschmar HA, Lassmann H: Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann Neurol 1995, 38: 788-796. 10.1002/ana.410380514
43. Irrcher I, Ljubicic V, Hood DA: Interactions between ROS and AMP kinase activity in the regulation of PGC-1alpha transcription in skeletal muscle cells. Am J Physiol Cell Physiol 2009, 296: C116-C123. 10.1152/ajpcell.00267.2007
44. Mungai PT, Waypa GB, Jairaman A, Prakriya M, Dokic D, Ball MK, Schumacker PT: Hypoxia triggers AMPK activation through reactive oxygen species-mediated activation of calcium release-activated calcium channels. Mol Cell Biol 2011, 31: 3531-3545. 10.1128/MCB.05124-11
45. Chen L, Na R, Gu M, Salmon AB, Liu Y, Liang H, Qi W, Van Remmen H, Richardson A, Ran Q: Reduction of mitochondrial H2O2 by overexpressing peroxiredoxin 3 improves glucose tolerance in mice. Aging Cell 2008, 7: 866-878. 10.1111/j.1474-9726.2008.00432.x
46. Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D: Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 2006, 127: 59-69. 10.1016/j.cell.2006.09.015
47. St-Pierre J, Drori S, Uldry M, Silvaggi JM, Rhee J, Jager S, Handschin C, Zheng K, Lin J, Yang W, Simon DK, Bachoo R, Spiegelman BM: Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 2006, 127: 397-408. 10.1016/j.cell.2006.09.024
48. Dringen R, Pfeiffer B, Hamprecht B: Synthesis of the antioxidant glutathione in neurons: supply by astrocytes of CysGly as precursor for neuronal glutathione. J Neurosci 1999, 19: 562-569.
49. Vargas MR, Johnson DA, Sirkis DW, Messing A, Johnson JA: Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis. J Neurosci 2008, 28: 13574-13581. 10.1523/JNEUROSCI.4099-08.2008
50. St-Pierre J, Lin J, Krauss S, Tarr PT, Yang R, Newgard CB, Spiegelman BM: Bioenergetic analysis of peroxisome proliferator-activated receptor + | coactivators 1alpha and 1beta (PGC-1alpha and PGC-1beta) in muscle cells. J Biol Chem 2003, 278: 26597-26603. 10.1074/jbc.M301850200
51. O'Neill LAJ, Hardie DG: Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature 2013, 493: 346-355. 10.1038/nature11862
52. Tornatore L, Thotakura AK, Bennett J, Moretti M, Franzoso G: The nuclear factor kappa B signaling pathway: integrating metabolism with inflammation. Trends Cell Biol 2012, 22: 557-566. 10.1016/j.tcb.2012.08.001
53. Storer PD, Xu J, Chavis J, Drew PD: Peroxisome proliferator-activated receptor-gamma agonists inhibit the activation of microglia and astrocytes: implications for multiple sclerosis. J Neuroimmunol 2005, 161: 113-122. 10.1016/j.jneuroim.2004.12.015
54. Haroon F, Drogemuller K, Handel U, Brunn A, Reinhold D, Nishanth G, Mueller W, Trautwein C, Ernst M, Deckert M, Schluter D: Gp130-dependent astrocytic survival is critical for the control of autoimmune central nervous system inflammation. J Immunol 2011, 186: 6521-6531. 10.4049/jimmunol.1001135
55. Li L, Lundkvist A, Andersson D, Wilhelmsson U, Nagai N, Pardo AC, Nodin C, Stahlberg A, Aprico K, Larsson K, Yabe T, Moons L, Fotheringham A, Davies I, Carmeliet P, Schwartz JP, Pekna M, Kubista M, Blomstrand F, Maragakis N, Nilsson M, Pekny M: Protective role of reactive astrocytes in brain ischemia. J Cereb Blood Flow Metab 2007, 28: 468-481. 10.1038/sj.jcbfm.9600546
56. Faulkner JR, Herrmann JE, Woo MJ, Tansey KE, Doan NB, Sofroniew MV: Reactive astrocytes protect tissue and preserve function after spinal cord injury. J Neurosci 2004, 24: 2143-2155. 10.1523/JNEUROSCI.3547-03.2004
57. Giatti S, Caruso D, Boraso M, Abbiati F, Ballarini E, Calabrese D, Pesaresi M, Rigolio R, Santos-Galindo M, Viviani B, Cavaletti G, Garcia-Segura LM, Melcangi RC: Neuroprotective effects of progesterone in chronic experimental autoimmune encephalomyelitis. J Neuroendocrinol 2012, 24: 851-861. 10.1111/j.1365-2826.2012.02284.x
58. Garay L, Deniselle MCG, Meyer M, Costa JJL, Lima A, Roig P, DeNicola AF: Protective effects of progesterone administration on axonal pathology in mice with experimental autoimmune encephalomyelitis. Brain Res 2009, 1283: 177-185. 10.1016/j.brainres.2009.04.057
59. Fonseca-Kelly Z, Nassrallah M, Uribe J, Khan RS, Dine K, Dutt M, Shindler KS: Resveratrol neuroprotection in a chronic mouse model of multiple sclerosis. Front Neurol 2012, 3: 84. 10.3389/fneur.2012.00084
60. Nimmagadda VK, Bever CT, Vattikunta NR, Talat S, Ahmad V, Nagalla NK, Trisler D, Judge SIV, Royal W, Chandrasekaran K, Russell JW, Makar TK: Overexpression of SIRT1 protein in neurons protects against experimental autoimmune encephalomyelitis through activation of multiple SIRT1 targets. J Immunol 2013, 190: 4595-4607.